26th March
2010
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis (RRMS)…
Leave a Reply
ABOUT
Your online resource center for Multiple Sclerosis Information
RECENT POSTS
29th November 2010
26th November 2010
22nd November 2010
19th November 2010
15th November 2010
Best Selling Book
Subscriptions
RSSContributors
Archives
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
Tags
abdominal wall
adenocarcinoma
amniocentesis
biopsy
blood test
brain
cancer therapy
central nervous system
danerous blood vessel condition
degenerative disease
depression
dopamine
gary null
good eating habits
lar-henrik krarup
lung cancer
molecular markers
ms
ms multiple scleroris
MS patients
ms symptoms
ms treatment
ms treatments
Multiple Sclerosis
multiple sclerosis disease
multiple sclerosis research
multiple sclerosis symptoms
multiple sclerosis wiki
multiple sclerosis wikipedia
neurotransmitter
overeating
stroke
stroke recovery
testing the fetus
testing women
treating lung cancer
ultrasound
women smokers